Factor XIa Inhibitor (Bayer) |
Factor XIa Inhibitor (Bayer) |
Phase 1 Clinical |
|
Blood Coagulation Disorders |
Details
|
SAL-0104 |
SAL-0104; SAL0104 |
Phase 1 Clinical |
Suzhou Genemen Biotech Co Ltd |
Embolism; Myocardial Infarction; Venous Thromboembolism; Stroke; Ischemic Attack, Transient; Cardiovascular Diseases; Venous Thrombosis |
Details
|
SKB-336 |
SKB-336 |
Phase 1 Clinical |
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd |
Thromboembolism |
Details
|
KN060 |
KN-060 |
Phase 1 Clinical |
Suzhou Alphamab Co Ltd |
Thromboembolism |
Details
|
BMS-262084 |
BMS-262084 |
Phase 1 Clinical |
Bristol-Myers Squibb Company |
Thrombosis |
Details
|
IONIS-FXIRX |
FXI-ASO; ISIS-FXIRX; BAY-2306001; IONIS-FXIRX; ISIS-404071; ISIS-416858 |
Phase 2 Clinical |
Ionis Pharmaceuticals Inc |
Venous Thromboembolism; Thrombosis |
Details
|
BAY-1831865 |
AB-012; BAY-1831865 |
Phase 1 Clinical |
Aronora |
Thrombosis |
Details
|
ONO-7269 |
ONO-7269 |
Phase 1 Clinical |
Ono Pharmaceutical Co Ltd |
Cerebral Infarction |
Details
|
BMS-986209 |
BMS-986209 |
|
Bristol-Myers Squibb Company |
|
Details
|
NIP-003 |
NIP003 |
Phase 1 Clinical |
National Institutes Of Pharmaceutical Research And Development Co Ltd |
Venous Thrombosis |
Details
|
SHR2285 |
SHR-2285 |
Phase 2 Clinical |
Jiangsu Hengrui Medicine Co Ltd |
Embolism; Venous Thromboembolism; Thrombosis |
Details
|
Fesomersen |
ION-957943; IONIS-FXI-LRx; BAY-2976217 |
Phase 1 Clinical |
Ionis Pharmaceuticals Inc |
Thromboembolism |
Details
|
Ir-CPI |
Ir-CPI |
Phase 1 Clinical |
|
|
Details
|
REGN-9933 |
REGN-9933 |
Phase 1 Clinical |
Regeneron Pharmaceuticals Inc |
|
Details
|
Milvexian |
BMS-986177; JNJ-70033093; JNJ-3093 |
Phase 1 Clinical |
Bristol-Myers Squibb Company |
Thromboembolism |
Details
|
ONO-7684 |
ONO-7684 |
|
Ono Pharmaceutical Co Ltd |
|
Details
|
BMS-962212 |
BMS-962212; BMS-96221202; BMS-962212-02 |
|
Bristol-Myers Squibb Company |
|
Details
|
Asundexian |
BAY-2433334 |
Phase 2 Clinical |
Bayer AG |
Stroke; Thromboembolism |
Details
|
EP-7041 |
EP-7041; HSK36273; HSK-36273; EP7041 |
Phase 2 Clinical |
Exithera |
Blood Coagulation Disorders; Coronavirus Disease 2019 (COVID-19); Thrombocytopenia; Thrombosis |
Details
|
MK-2060 |
MK-2060 |
Phase 2 Clinical |
Merck Sharp & Dohme Corp |
Uremia; Kidney Failure, Chronic |
Details
|
Osocimab |
BAY-1213790 |
Phase 2 Clinical |
Bayer AG |
Thromboembolism; Uremia; Kidney Failure, Chronic |
Details
|
Xisomab 3G3 (Oregon Health & Science University) |
AB-022; AB-023 |
Phase 2 Clinical |
Oregon Health & Science University |
Solid tumours; Multiple Myeloma; Lymphoma |
Details
|
Abelacimab |
MAA-868; NOV-12 |
Phase 3 Clinical |
Novartis Pharma Ag |
Pulmonary Embolism; Venous Thromboembolism; Stroke; Atrial Fibrillation; Venous Thrombosis |
Details
|